PT-141

PT‑141 (Bremelanotide) is a melanocortin receptor agonist FDA‑approved for female hypoactive sexual desire disorder and used off‑label for male erectile dysfunction, libido enhancement, and general sexual enhancement. Users most often take about 1 mg per day (range 0.2–2.5 mg) with no consistent timing or cycling, clinicians usually prescribe 1–2 mg daily (also without set timing or cycling), and positive feedback is highest for general sexual enhancement (~87 % of reports) and moderate for male erectile dysfunction/libido (~75 %), while reports for female sexual dysfunction are lower (~33 %). The off‑label evidence base is thin, with most exploratory indications lacking posted results.

Half-life~2 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.93.42.33.52.84.0

Research Evidence

Evidence shape

The peptide has high‑level human evidence, with the strongest trials being Phase 3 studies in hypoactive sexual desire disorder and female sexual arousal disorder. Across ten registered trials (over two thousand participants) there are four blinded results, five different sponsors and ten linked publications, covering nine indications but only two with posted results. Six indications remain thin or exploratory, one is animal‑only and five are single‑trial long‑tail, showing where data are absent or limited.

Depthhow much
10 registered trials
9 completed · 4 with posted results · 1 recruiting / active · combined n=2089
Breadthhow many areas
9 indications mapped
2 with results · 6 thin / exploratory · 1 animal-only · 5 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
4 blinded with results · 5 distinct sponsors · AE rows aggregated from 3 trials · 10 linked publications on registered trials
Breadth and depth30 rows captured
Human
direct clinical signal
29
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

PT-141 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Better Peptide
US
100 mg
$29.99
$0.3/mg
2
Treasure Coast Peptides
--
100 mg
$34.97
$0.35/mg
3
High Purity Peptides
Hong Kong
100 mg×10
$50.00
$0.5/mg
4
Saiyan Med
US
100 mg×10
$70.00
$0.7/mg
5
Uther
unknown
100 mg×10
$75.00
$0.75/mg
6
Chimera Peptides
CN
100 mg×10
$109.00
$1.09/mg

price offers can be sorted by column · 21 out-of-stock offers not shown

1-6 of 259

PT-141 dosing & protocol

How PT-141 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 28
Typical dose
1.8 mg1.8 mg – 8 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 16 reported doses · darker = more
Frequency
twice daily
Route
subQ

Research trials administered PT‑141 subcutaneously twice daily, most often at a fixed 1.75 mg dose, with a reported range from 1.8 mg up to 8 mg per administration.

28 sources
Clinician practice
Doctor & published-protocol guidance · n = 5
Typical dose
1.8 mg1 mg – 2 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 7 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Across five clinician sources, the dose sits at 1–2 mg subcutaneously, with 1.75 mg appearing most often; three sources specify daily dosing, the prescribing monograph specifies as-needed administration at 1.75 mg, and no cycling protocol was captured.

5 sources
Anecdotal
Community-reported real-world use · n = 68
Typical dose
1 mg200 µg – 2.5 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 83 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users most often report a dose of about 1 mg of PT‑141 taken subcutaneously, with individual reports ranging from 200 µg up to 2.5 mg.

68 sources

Regulatory safety notes

Warnings and precautions
  • • Transient increase in blood pressure and decrease in heart rate: Occurs after each dose and usually resolves within 12 hours. Consider the patient's cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is w…
  • • Focal hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Higher risk in patients with darker skin and with daily dosing. Resolution was not confirmed in some patients. Co…
  • • Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Improved for most patients with the second dose. Consider discontinuing VYLEE…
Contraindications
  • • VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions (5.1) ]. Uncontrolled hypertension or known cardiovascular disease.
Drug interactions
  • • VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. (7.1) VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing…

Related peptides

Kisspeptin-10HCGTriptorelinOxytocinGonadorelin